BETFIRSO
Live / Applied — Third extension granted (statement of use) (as of 04 Feb 2026)
What this means for you
Not registered yet, but its 08 Feb 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97786648
- Mark type
- Stylized text
- Filed
- 08 Feb 2023
- Published for opposition
- 11 Jun 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways
Owner
- Constellation Pharmaceuticals, Inc., Boston, MA, US
- Constellation Pharmaceuticals, Inc., Boston, MA, US
Prosecution history
- 04 Feb 2026 — SOU EXTENSION 3 GRANTED
- 04 Feb 2026 — SOU EXTENSION 3 FILED
- 04 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Aug 2025 — SOU EXTENSION 2 GRANTED
- 01 Aug 2025 — SOU EXTENSION 2 FILED
- 01 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 09 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 09 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 09 May 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 09 May 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 09 May 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 04 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Feb 2025 — SOU EXTENSION 1 GRANTED
- 03 Feb 2025 — SOU EXTENSION 1 FILED